Fecal Biomarker Discovery for IBD

Fecal biomarkers are now being widely used to diagnose and track IBD. There are a few advantages to fecal biomarkers, over other biomarkers:

• The ease of collecting feces makes it convenient to repeat sampling for a period of time if necessary.
• Biomarkers in the fecal stream get directly exposed to the inflamed intestine, so they reflect inflammation severity and level.
• More so between bowel biomarkers and intestinal inflammation than between serum biomarkers and non-gastrointestinal inflammation.

Fig. 1. Novel fecal biomarkers that precede clinical diagnosis of ulcerative colitis. (Galipeau et al., 2021)

Fecal Biomarker Discovery Services

As a research service provider for IBD research, Ace Therapeutics offers comprehensive fecal biomarker exploratory research services. Our expert team collaborates with clients throughout the project, providing tailored support from study design to result interpretation.

Identification of Fecal Biomarkers 

We have established the analytical technology ELISA, Luminex assays, flow cytometry, qPCR/ddPCR, LC-MS/MS in our laboratory. With these tools, we help pharmaceutical companies identify novel fecal biomarkers.

Analysis of Fecal Biomarkers in IBD

Ace Therapeutics has decades of expertise in assay design and fecal sample processing. This extensive expertise ensures that our clients receive precise and reliable fecal biomarker analysis services tailored specifically for drug discovery initiatives related to IBD.

• Our research involves a multifaceted approach to explore the capabilities of fecal biomarkers in differentiating between various types of bowel conditions, particularly focusing on the distinction between organic diseases and functional disorders.
• We investigate the role of fecal biomarkers in predicting histological activity within IBD patients..
• Our studies encompass the detection of mucosal inflammation, a critical aspect of IBD progression and flare-ups. Identifying markers of inflammation within fecal samples can aid in monitoring disease activity and tailoring therapeutic interventions more effectively.
• We conduct comparative analyses of the efficacy of various IBD medications. By utilizing fecal biomarkers as endpoints in our assessments, we provide comprehensive evaluations of treatment responses, contributing valuable data to the broader field of IBD research and drug development.

Ace Therapeutics helps clients validate reliable pharmacodynamic (PD) fecal biomarker assays that provide invaluable guidance within their IBD drug development programs. If you are interested in our fecal biomarker discovery services, please do not hesitate to contact us.